Agilent Technologies and BioNanomatrix to Develop Genetic Analysis System Using Nanoscale Whole Genome Imaging Technology
BioNanomatrix is developing pioneering technology that enables nanoscale single molecule identification and analysis of the entire genome, delivering single-molecule sensitivity in a highly parallel format. The company's patented analytic platform based on this technology has the potential to provide rapid, comprehensive and cost-effective ultra-high resolution analyses of DNA. The two companies intend to collaborate closely in the development of an integrated system and applications.
"BioNanomatrix's unique nanoscale whole genome imaging and analysis technology, with sensitivity at the level of the single molecule, has the potential to enable a number of important new applications for life sciences research and clinical medicine," said Nick Roelofs, vice president and general manager of the Life Sciences Solutions Unit at Agilent. "We are committed to continuing our leadership in developing important new technologies and solutions for our customers, and we look forward to collaborating with the BioNanomatrix team to enable these powerful new capabilities to reach the marketplace."
Further details of the agreement were not disclosed.
Most read news
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.